Stein A - Search Results

1

Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.

Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. Stein A, et al. Eur Urol. 2013 Dec;64(6):994-1002. doi: 10.1016/j.eururo.2012.11.032. Epub 2012 Nov 21. Eur Urol. 2013. PMID: 23219086 Clinical Trial.

2

Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.

Stein A, Wang W, Carter AA, Chiparus O, Hollaender N, Kim H, Motzer RJ, Sarr C. Stein A, et al. BMC Cancer. 2012 Jul 23;12:311. doi: 10.1186/1471-2407-12-311. BMC Cancer. 2012. PMID: 22824201 Free PMC article. Clinical Trial.

3

BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.

Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP, Hochhaus A. Stein AM, et al. Clin Cancer Res. 2011 Nov 1;17(21):6812-21. doi: 10.1158/1078-0432.CCR-11-0396. Epub 2011 Sep 8. Clin Cancer Res. 2011. PMID: 21903771

4

Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors.

Xu S, Zhang N, Rinne ML, Sun H, Stein AM. Xu S, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1653-1665. doi: 10.1002/psp4.12962. Epub 2023 May 31. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37186155 Free PMC article.

5

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.

Goel V, Hurh E, Stein A, Nedelman J, Zhou J, Chiparus O, Huang PH, Gogov S, Sellami D. Goel V, et al. Among authors: stein a. Cancer Chemother Pharmacol. 2016 Apr;77(4):745-55. doi: 10.1007/s00280-016-2982-1. Epub 2016 Feb 22. Cancer Chemother Pharmacol. 2016. PMID: 26898300

6

Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included.

Alaybeyoglu B, Cheng HWJ, Doshi KA, Makani V, Stein AM. Alaybeyoglu B, et al. Among authors: stein am. J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):447-464. doi: 10.1007/s10928-020-09734-9. Epub 2021 Feb 8. J Pharmacokinet Pharmacodyn. 2021. PMID: 33558979

7

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.

Stein AM, Ramakrishna R. Stein AM, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):258-266. doi: 10.1002/psp4.12169. Epub 2017 Apr 4. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28375563 Free PMC article.

8

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.

Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL. Mueller KT, et al. Among authors: stein am. Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6. Clin Cancer Res. 2018. PMID: 30190371 Free PMC article.

9

Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Ahmed S, Ellis M, Li H, Pallucchini L, Stein AM. Ahmed S, et al. J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):287-304. doi: 10.1007/s10928-019-09638-3. Epub 2019 Apr 29. J Pharmacokinet Pharmacodyn. 2019. PMID: 31037615

In this manuscript, previous work on characterizing target inhibition at steady state using the AFIR metric (Stein and Ramakrishna in CPT Pharmacomet Syst Pharmacol 6(4):258-266, 2017) is extended to include a "target-tissue" compartment and the shedding of membrane …

In this manuscript, previous work on characterizing target inhibition at steady state using the AFIR metric (Stein and Ramakrishna in …

10

Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches.

Chaudhury A, Zhu X, Chu L, Goliaei A, June CH, Kearns JD, Stein AM. Chaudhury A, et al. Among authors: stein am. J Clin Pharmacol. 2020 Oct;60 Suppl 1:S147-S159. doi: 10.1002/jcph.1691. J Clin Pharmacol. 2020. PMID: 33205434 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,939 results

Search Page